We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, acute and chronic respiratory, gynecology, pediatrics, neurology, psychiatry, arthritis, and pain/analgesics, as well as in-vitro fertilization, cancer, multi-therapy, cosmetology, and dermatology. The company has an in-licensing partnership with Microlife to offer a range of medical devices comprising blood pressure monitors, blood glucose monitors, infra-red thermometers, nebulizers, and pregnancy testing kits under the CIRCA brand. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
TODAY'S HIGH
721.4
TODAY'S LOW
675
52 WEEK HIGH
863
52 WEEK LOW
623.05
% of Shares Held by
All Insider
78.94%
% of Shares Held by
Institutions
13.67%
% of Float Held by
Institutions
64.91%
Number of Institutions
Holding Shares
32
MARKET CAP
9262.89 Cr.
ETERPRISE VALUE
9606.41 Cr.
NO. OF SHARES
13.59 Cr.
BOOK VALUE
140.457
DIV. YIELD
6.01%
DEBT
96.61 Cr.
GROSS PROFIT
1067.65 Cr.
CASH
219.36 Cr.
REVENUE
1326.16 Cr.
REVENUE/SHARE
97.606
Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
---|---|---|---|---|
Investments | 0 | -294.63 Cr. | 287.99 Cr. | 34.96 Cr. |
Change To Liabilities | 0 | 2.56 Cr. | 15.93 Cr. | -6.65 Cr. |
Total cashflows from Investing Activities | 0 | -323.35 Cr. | 123.23 Cr. | -5.05 Cr. |
Net Borrowings | 0 | -5.93 Cr. | -184.11 Cr. | -200.21 Cr. |
Total Cash from Financing Activities | 0 | -82.39 Cr. | -334.59 Cr. | -221.05 Cr. |
Other Liabilities | 0 | 11.85 Cr. | -6.97 Cr. | -11.82 Cr. |
Total Assets | 0 | 0 | 0 | 89.20 Lakhs |
Net Income | 0 | 355.13 Cr. | 296.49 Cr. | 290.79 Cr. |
Change in Cash | 0 | -30.39 Cr. | 59.80 Cr. | -3.10 Cr. |
Effect of Exchange Rate | 0 | 0 | 0 | 0 |
Total Cash from Operating Activities | 0 | 375.36 Cr. | 271.16 Cr. | 222.99 Cr. |
Depreciation | 0 | 42.30 Cr. | 49.85 Cr. | 36.05 Cr. |
Other Cashflows from Investing Activities | 0 | -4 Lakhs | 1.29 Cr. | 8.56 Cr. |
Dividends Paid | 0 | -74.67 Cr. | -38.96 Cr. | -38.96 Cr. |
Change to Inventory | 0 | -24.99 Cr. | 13.17 Cr. | -17.20 Cr. |
Change to Account Receivables | 0 | 15.89 Cr. | -74.78 Cr. | -17.55 Cr. |
Other Cashflows from Financing Activities | 0 | -1.78 Cr. | -11.51 Cr. | -21.73 Cr. |
Change to Net Income | 0 | -28.08 Cr. | -22.93 Cr. | -50.91 Cr. |
Capital Expenditures | 0 | -25.76 Cr. | -151.28 Cr. | -38 Cr. |
Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
---|---|---|---|---|
Research Development | None | None | None | None |
Effect of Accounting Charges | None | None | None | None |
Income Before Tax | 0 | 394.49 Cr. | 331.35 Cr. | 317.35 Cr. |
Minority Interest | 0 | 20 k | 20 k | 18.31 Cr. |
Net Income | 420.25 Cr. | 387.60 Cr. | 321.85 Cr. | 308.88 Cr. |
Selling General Administrative | 0 | 243.91 Cr. | 231.68 Cr. | 245.29 Cr. |
Gross Profit | 1067.65 Cr. | 950.71 Cr. | 882.91 Cr. | 809.58 Cr. |
Ebit | 420.25 Cr. | 387.60 Cr. | 321.85 Cr. | 308.88 Cr. |
Operating Income | 420.25 Cr. | 387.60 Cr. | 321.85 Cr. | 308.88 Cr. |
Other Operating Expenses | 330.44 Cr. | 276.20 Cr. | 279.12 Cr. | 219.05 Cr. |
Interest Expense | 0 | -1.80 Cr. | -2.16 Cr. | -22.89 Cr. |
Extraordinary Items | None | None | None | None |
Non Recurring | None | None | None | None |
Other Items | None | None | None | None |
Income Tax Expense | 0 | 39.36 Cr. | 34.84 Cr. | 26.21 Cr. |
Total Revenue | 1326.16 Cr. | 1192.64 Cr. | 1058.18 Cr. | 967.20 Cr. |
Total Operating Expenses | 905.91 Cr. | 805.03 Cr. | 736.33 Cr. | 658.32 Cr. |
Cost of Revenue | 0 | 241.93 Cr. | 175.26 Cr. | 157.61 Cr. |
Total Other Income Expense Net | 26.09 Cr. | 6.88 Cr. | 9.49 Cr. | 8.47 Cr. |
Discontinued Operations | None | None | None | None |
Net Income from Continuous Ops. | 0 | 355.13 Cr. | 296.50 Cr. | 291.14 Cr. |
Net Income Applicable to Common Shares | 0 | 355.13 Cr. | 296.49 Cr. | 290.79 Cr. |
Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
---|---|---|---|---|
Intangible Assets | 0 | 684.07 Cr. | 698.46 Cr. | 613.60 Cr. |
Capital Surplus | 0 | 0 | 0 | 1.34 Cr. |
Total Liabilities | 0 | 258.35 Cr. | 255.97 Cr. | 384.83 Cr. |
Stock Holder Equity | 0 | 1576.42 Cr. | 1296.33 Cr. | 1150.51 Cr. |
Minority Interest | 0 | 20 k | 0 | 18.31 Cr. |
Other Liabilities | 65.64 Cr. | 34.23 Cr. | 30.61 Cr. | 20.02 Cr. |
Total Assets | 0 | 1834.78 Cr. | 1552.30 Cr. | 1553.66 Cr. |
Common Stock | 0 | 13.57 Cr. | 13.57 Cr. | 13.75 Cr. |
Retained Earnings | 0 | 1550.31 Cr. | 1271.34 Cr. | 1134.22 Cr. |
Other Liabilities | 0 | 86.97 Cr. | 85.13 Cr. | 79 Cr. |
Good Will | 0 | 93.47 Cr. | 93.47 Cr. | 93.58 Cr. |
Treasury Stock | 0 | 12.53 Cr. | 11.41 Cr. | 1.19 Cr. |
Other Assets | 274.54 Cr. | 226.39 Cr. | 190.26 Cr. | 167.70 Cr. |
Cash | 0 | 36.91 Cr. | 67.30 Cr. | 7.50 Cr. |
Current Liabilities | 0 | 166.93 Cr. | 164.69 Cr. | 305.53 Cr. |
Long Term Asset Charges | 0 | 200.63 Cr. | 170.91 Cr. | 144.79 Cr. |
Short Long Term Debt | 0 | 0 | 0 | 176.13 Cr. |
Other Stockholder Equity | 0 | 12.53 Cr. | 11.41 Cr. | 1.19 Cr. |
Property Plant Equipment | 0 | 77.87 Cr. | 87.27 Cr. | 56.07 Cr. |
Total Cur. Assets | 0 | 467.04 Cr. | 479.61 Cr. | 581.77 Cr. |
Long Term Investments | 425.34 Cr. | 285.91 Cr. | 3.20 Cr. | 40.91 Cr. |
Net Tangible Assets | 0 | 798.87 Cr. | 504.39 Cr. | 443.32 Cr. |
Short Term Investments | 167.03 Cr. | 92.42 Cr. | 20 k | 20 k |
Net Receivables | 0 | 172.53 Cr. | 206.90 Cr. | 136.80 Cr. |
Long Term Debt | 0 | 0 | 0 | 29.30 Lakhs |
Inventory | 0 | 94.46 Cr. | 69.47 Cr. | 82.65 Cr. |
Accounts Payable | 0 | 102.61 Cr. | 100.05 Cr. | 84.12 Cr. |